Inactivated Influenza Vaccine
Vaccine / immunological product
What it is used for
Active immunization against current existing Influenza. Clinical selection for Inactivated Influenza Vaccine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Vaccine / immunological product. Confirm site-specific dose, duration and monitoring before prescribing.
Warnings
Observe 15 minutes post-dose if high anaphylaxis concern. Correct injection technique and site. Report AEFI via national systems.
Possible side effects
Local pain, low-grade fever, myalgia. Serious: anaphylaxis, vaccine-specific rare events (e.g. intussusception historically with some rotavirus products).
Storage
Store as labelled. Keep out of reach of children.
No reviewed patient-education article is available. The fields shown are from the currently verified medicine record and unavailable fields are not inferred.